Delivery Order SPE2DB20D3103-SPE2DB25FQ3S3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Phytonadione 1 mg/0.5 mL syringes with a ceiling value of $20,559.12. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,012.32 to AmerisourceBergen Drug Corp for Phytonadione 1 mg/0.5 mL syringes (0.5 mL units). This is a firm fixed-price delivery order with no set-aside designation, executed on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Department of Defense Medical Supply Chain awarded a $2,701.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Phytonadione 10 mg/ml ampules, with an ultimate completion date of August 4, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Phytonadione 1 mg/0.5 mL syringes valued at $2,716.90, with completion targeted for July 21, 2025. This is a firm fixed-price contract with no set-aside designation, meaning it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Phytonadione 10 mg/ml in ampule form, with a contract ceiling value of $2,026.26 and an ultimate completion date of September 4, 2025. This competitively awarded, non-set-aside delivery order carries firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Phytonadione 1 mg/0.5 mL syringes with a ceiling value of $3,132.07 under firm fixed price terms. The delivery order is not set-aside and represents a competitively awarded procurement. This award is a child contract issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $10,492.26 to AmerisourceBergen Drug Corp for the supply of Phytonadione 1 mg/0.5 mL syringes in 0.5 mL units. This contract, issued on August 22, 2025, with an ultimate completion date of August 25, 2025, represents a firm fixed-price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Phytonadione, commonly known as vitamin K1,...
- The Defense Logistics Agency awarded a $55,089.27 delivery order to AmerisourceBergen Drug Corp for Phytonadione 1 mg/0.5 mL syringes on July 3, 2025, with an ultimate completion date of July 7, 2025. This is a firm fixed price, non-set-aside contract utilizing a competitively awarded delivery order model. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Phytonadione, commonly known as Vitamin K1, is a critical pharmaceutical product used...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,774.99 to AmerisourceBergen Drug Corp for Phytonadione 1 mg/0.5 mL syringes on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order, which carries no set-aside designation, was competitively awarded and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. Phytonadione, commonly known as Vitamin K1, is a critical pharmaceutical used...
- The Defense Logistics Agency awarded a $2,333.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Phytonadione 1 mg/0.5 mL syringes in 0.5 mL unit doses. The contract, which is classified as a child order under a larger vehicle, carries an ultimate completion date of September 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was utilized for this competitive...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3S3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,308.92 to AmerisourceBergen Drug Corp for Phytonadione 1 mg/0.5 mL syringes on September 17, 2025, with completion targeted for September 18, 2025. The award was made on a firm fixed-price basis with no set-aside designation, indicating competitive selection. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs. This delivery order is issued under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which functions as a comprehensive global pharmaceutical support vehicle. The Phytonadione product represents a vitamin K analog commonly used in military and veteran healthcare systems for coagulation management and related medical applications. AmerisourceBergen Drug Corp's extensive federal contract portfolio demonstrates its capacity to fulfill diverse pharmaceutical supply requirements across multiple therapeutic domains, with delivery orders ranging significantly in value. The company's participation in the DLA's Pharmaceutical Prime Vendor program enables it to supply critical medical commodities including specialty medications, brand-name and generic drugs, and related healthcare materials to support military health programs globally, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/17/25 |